| A | B | C | D | E | F | G | H | I | J | K | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | |||||||||||
| 2 | Name | Indication | Approved | Mechanism | Economics | IP | Price EUR | 184 | |||
| 3 | Erbitux (cetuximab) | 3L mCRC | EGFR mab | BMY/LLY(IMCL) | Shares | 434.777878 | Q222 | ||||
| 4 | Rebif | Multiple Sclerosis | Interferon | MC EUR | 79999.129552 | ||||||
| 5 | Gonal-F (follitropin) | Infertility | Recombinant | Cash EUR | 1951 | Q322 | |||||
| 6 | Concor | Debt EUR | 11050 | Q322 | |||||||
| 7 | Euthyrox (levothyroxine) | TH Deficiency | EV EUR | 89098.129552 | |||||||
| 8 | Raptiva | Psoriasis | |||||||||
| 9 | Saizen (somatropin) | GH Deficiency | |||||||||
| 10 | Bavencio (avelumab) | Oncology | PD-1 mab | ||||||||
| 11 | Glucophage | Type 2 Diabetes | |||||||||
| 12 | Phase | ||||||||||
| 13 | |||||||||||
| 14 | |||||||||||
| 15 | |||||||||||
| 16 | |||||||||||
| 17 | Cilgenitide and safinimide failed. | ||||||||||
| 18 | berzosertib (ATR inhibitor) failed |